FDA's Next-Generation Review Process: Avoiding the "Crisis Mentality"

There are changes coming to FDA's drug review process that, over the long term, should make the system more predictable and increase the chances for a first-cycle approval. Until then, expect a less forgiving agency when it comes to incomplete submissions-and challenges that may threaten the sanctity of priority reviews.

Kate Rawson

More first-cycle approvals. That’s what every sponsor wants: a better chance of receiving that coveted approval letter on the first...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet